The latest price target for Co-Diagnostics (NASDAQ:CODX) was reported by HC Wainwright & Co. on November 11, 2024. The analyst firm set a price target for $1.50 expecting CODX to rise to within 12 months (a possible 47.06% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Co-Diagnostics (NASDAQ:CODX) was provided by HC Wainwright & Co., and Co-Diagnostics reiterated their neutral rating.

There is no last upgrade for Co-Diagnostics

The last downgrade for Co-Diagnostics Inc happened on March 20, 2023 when HC Wainwright & Co. changed their price target from $6 to $3 for Co-Diagnostics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Co-Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Co-Diagnostics was filed on November 11, 2024 so you should expect the next rating to be made available sometime around November 11, 2025.

While ratings are subjective and will change, the latest Co-Diagnostics (CODX) rating was a reiterated with a price target of $1.50 to $1.50. The current price Co-Diagnostics (CODX) is trading at is $1.02, which is out of the analyst’s predicted range.